Effective June 4, 2025, Corewell Health Laboratories will include a preliminary result of >10000 mIU/mL for Beta Human Chorionic Gonadotropin (hCG + β) (LAB142) specimens that require dilution. The preliminary result will provide a quick insight on the status of the βhCG quantification analysis. It is important to remember that these results are not definitive, therefore final interpretation should be made alongside the fully validated results.
Browsing Category
Chemistry
Effective March 21, 2025, Corewell Health Laboratories will update the preferred specimen type for β-hCG testing from plasma to serum (mint green top, lithium heparin gel to gold top, serum separator-SST gel). The move to serum is mostly driven by the laboratory’s need to reduce assay performance problems that can occur sporadically with the use of plasma. Although serum is the preferred specimen type plasma will remain an acceptable container.
If you have questions regarding the preanalytical handling process and the optimum tube offering, contact the lab for support.
TEST INFORMATION
Effective Wednesday, January 1, 2025, the in-house test, Research Creatine Kinase MB Fraction (CK-MB) (LAB2111534) will be made inactive. Recommended alternative testing is CK-MB (CK-2) (TC:17581) which is referred to Quest Diagnostics.
For questions or additional information, please use the Contact Us link above.
An equipment issue resulted in artificially high parathyroid hormone results for some patients from July 31- August 17, 2024. We have repeated testing on the potentially affected samples, corrections were made as necessary, and providers for the impacted patients have been notified.
Review of quality indicator data suggested that issue affecting the results began July 31. Not all patient values were affected, but those that were had artificially high values. The laboratory repeated all PTH testing from this instrument for which remaining sample was available, corrected results, and contacted providers via epic inbox message for CHW providers and other appropriate means for CHW affiliates and external providers whose lab work is performed at CHW in Grand Rapids. Providers of potentially impacted patients whose samples could not be repeated have also been notified.
Effective Thursday, April 18, 2024, Corewell Health Laboratory will discontinue the send out test Hepatitis A IgG Antibody, Serum (Mayo Test ID: HAIGG). This test has been made obsolete by Mayo Clinic Laboratories. We recommend to our healthcare providers the following in-house testing:
1.Hepatitis A Total Antibody (LAB1230596): intended for the clinical laboratory diagnosis of acute or past hepatitis A virus infection in persons with signs or symptoms of hepatitis and in persons at increased risk for hepatitis A infection, to identify HAV susceptible individuals and to determine the presence of an antibody response to HAV in vaccine recipients.
2.Hepatitis A Antibody, IgM (LAB7980): intended for use as an aid in the laboratory diagnosis of an acute or recently acquired hepatitis A virus infection.
Effective February 7, 2024, at 7:30 AM, Corewell Health West Laboratories will go live with a new reference range for the calculated Anion Gap (AG). The AG reference range will be adjusted to align with recent reference range studies.
The following will be the new normal reference ranges for AG:
Anion Gap: 5 – 14 mmol/L
Effective December 20, 2023, Rheumatoid Factor, IgM, Quantitative will be replaced with Rheumatoid Factor.
Chemistry, General Information, Test Spotlight
Microalbumin/Creatinine, Random Urine Result Comment Update
Effective January 4, 2023, the process for reporting the Microalbumin/Creatinine ratio was changed for situations where one of the results, microalbumin and/or creatinine, is below or above the assay’s analytical measuring range (AMR).